Israel 2834 Not Applicable (Primary Standard Industrial Classification Code Number) As filed with the Securities and Exchange Commission on January 22, 2026 Registration No. 333-292528 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REDHILL BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) (State or other jurisdiction o ...

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 As filed with the Securities and Exchange Commission on December 31, 2025 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REDHILL BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) RedHill Biopharma In ...

Core Insights - Cumberland Pharmaceuticals announced significant results from its Phase 2 FIGHT DMD clinical trial, demonstrating a 5.4% improvement in cardiac function for patients with Duchenne muscular dystrophy (DMD) [1][3][4] Group 1: Clinical Trial Results - The Phase 2 FIGHT DMD trial showed that high-dose ifetroban treatment resulted in a 3.3% improvement in left ventricular ejection fraction (LVEF) compared to placebo [3] - When compared to propensity-matched natural history controls, high-dose treatment provided a significant 5.4% overall improvement in LVEF, while control patients experienced a 3.6% decline [3] - These improvements in cardiac function could lead to enhanced quality of life and survival for DMD patients [3] Group 2: Drug Information - Ifetroban is an oral thromboxane receptor antagonist that has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for DMD-related heart disease [4][7][8] - If approved, ifetroban would be the first therapy specifically indicated for DMD-related heart disease [8] Group 3: Company and Industry Context - Cumberland Pharmaceuticals is focused on developing treatments for rare diseases, with a growing portfolio of patents related to ifetroban for DMD [5][11] - The company is preparing for an end-of-Phase-2 meeting with the FDA to discuss the next steps for ifetroban's development and commercialization [5] - Current therapies for DMD primarily focus on preserving muscle function, highlighting the urgent need for treatments addressing cardiac complications [4][6]